438 related articles for article (PubMed ID: 30308481)
1. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
Cheng M; Ma D; Zhi K; Liu B; Zhu W
Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
[TBL] [Abstract][Full Text] [Related]
2. Galactosylated chitosan/5-fluorouracil nanoparticles inhibit mouse hepatic cancer growth and its side effects.
Cheng MR; Li Q; Wan T; He B; Han J; Chen HX; Yang FX; Wang W; Xu HZ; Ye T; Zha BB
World J Gastroenterol; 2012 Nov; 18(42):6076-87. PubMed ID: 23155336
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of galactosylated chitosan/5-fluorouracil nanoparticles and its characteristics, in vitro and in vivo release studies.
Cheng M; Han J; Li Q; He B; Zha B; Wu J; Zhou R; Ye T; Wang W; Xu H; Hou Y
J Biomed Mater Res B Appl Biomater; 2012 Nov; 100(8):2035-43. PubMed ID: 22865703
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and its inhibition of liver cancer characteristics in vitro and in vivo.
Cheng M; Gao X; Wang Y; Chen H; He B; Xu H; Li Y; Han J; Zhang Z
Mar Drugs; 2013 Sep; 11(9):3517-36. PubMed ID: 24048270
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory of active dual cancer targeting 5-Fluorouracil nanoparticles on liver cancer
Cheng M; Dai D
Front Oncol; 2022; 12():971475. PubMed ID: 35992879
[TBL] [Abstract][Full Text] [Related]
6. Glycyrrhetinic acid-modified chitosan nanoparticles enhanced the effect of 5-fluorouracil in murine liver cancer model via regulatory T-cells.
Cheng M; Xu H; Wang Y; Chen H; He B; Gao X; Li Y; Han J; Zhang Z
Drug Des Devel Ther; 2013; 7():1287-99. PubMed ID: 24187487
[TBL] [Abstract][Full Text] [Related]
7. Optimized synthesis of glycyrrhetinic acid-modified chitosan 5-fluorouracil nanoparticles and their characteristics.
Cheng M; Chen H; Wang Y; Xu H; He B; Han J; Zhang Z
Int J Nanomedicine; 2014; 9():695-710. PubMed ID: 24493926
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of liver-targeting dual-ligand modified GCGA/5-FU nanoparticles and their characteristics in vitro and in vivo.
Cheng M; Gao X; Wang Y; Chen H; He B; Li Y; Han J; Zhang Z
Int J Nanomedicine; 2013; 8():4265-76. PubMed ID: 24232303
[TBL] [Abstract][Full Text] [Related]
9. 5-Fluorouracil nanoparticles inhibit hepatocellular carcinoma via activation of the p53 pathway in the orthotopic transplant mouse model.
Cheng M; He B; Wan T; Zhu W; Han J; Zha B; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
PLoS One; 2012; 7(10):e47115. PubMed ID: 23077553
[TBL] [Abstract][Full Text] [Related]
10. Galactosylated Chitosan-Functionalized Mesoporous Silica Nanoparticle Loading by Calcium Leucovorin for Colon Cancer Cell-Targeted Drug Delivery.
Liu W; Wang F; Zhu Y; Li X; Liu X; Pang J; Pan W
Molecules; 2018 Nov; 23(12):. PubMed ID: 30486276
[TBL] [Abstract][Full Text] [Related]
11. Cytocompatible chitosan-graft-mPEG-based 5-fluorouracil-loaded polymeric nanoparticles for tumor-targeted drug delivery.
Antoniraj MG; Ayyavu M; Henry LJK; Nageshwar Rao G; Natesan S; Sundar DS; Kandasamy R
Drug Dev Ind Pharm; 2018 Mar; 44(3):365-376. PubMed ID: 28835136
[TBL] [Abstract][Full Text] [Related]
12. Preliminary pharmacology of galactosylated chitosan/5-fluorouracil nanoparticles and its inhibition of hepatocellular carcinoma in mice.
Cheng M; Liu Z; Wan T; He B; Zha B; Han J; Chen H; Yang F; Li Q; Wang W; Xu H; Ye T
Cancer Biol Ther; 2012 Dec; 13(14):1407-16. PubMed ID: 22954702
[TBL] [Abstract][Full Text] [Related]
13. Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma.
Varshosaz J; Hassanzadeh F; Sadeghi H; Khadem M
J Liposome Res; 2012 Sep; 22(3):224-36. PubMed ID: 22385296
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer efficacy of biotinylated chitosan nanoparticles in liver cancer.
Cheng M; Zhu W; Li Q; Dai D; Hou Y
Oncotarget; 2017 Aug; 8(35):59068-59085. PubMed ID: 28938619
[TBL] [Abstract][Full Text] [Related]
15. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Wang Q; Zhang L; Hu W; Hu ZH; Bei YY; Xu JY; Wang WJ; Zhang XN; Zhang Q
Nanomedicine; 2010 Apr; 6(2):371-81. PubMed ID: 19699319
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticles of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) for cancer chemotherapy: preparation, characterization--in-vitro drug release and anti-tumour activity.
Yan C; Chen D; Gu J; Qin J
J Pharm Pharmacol; 2006 Sep; 58(9):1177-81. PubMed ID: 16945175
[TBL] [Abstract][Full Text] [Related]
17. Design and evaluation of galactosylated chitosan/graphene oxide nanoparticles as a drug delivery system.
Wang C; Zhang Z; Chen B; Gu L; Li Y; Yu S
J Colloid Interface Sci; 2018 Apr; 516():332-341. PubMed ID: 29408121
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Exenatide loaded Biotinylated Trimethylated Chitosan/HP- 55 Nanoparticles.
Guo H; Yan X; Tang H; Zhang X
Curr Drug Deliv; 2022; 19(1):32-40. PubMed ID: 34126896
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and characterization of biotin modified cholesteryl pullulan as a novel anticancer drug carrier.
Yang W; Wang M; Ma L; Li H; Huang L
Carbohydr Polym; 2014 Jan; 99():720-7. PubMed ID: 24274563
[TBL] [Abstract][Full Text] [Related]
20. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
